Camptothecin prodrug block copolymer micelles with high drug loading and target specificity

The clinical efficacy of cytotoxic drugs in the treatment of cancer is often hampered by poor pharmacodynamics and systemic toxicity. Here, we describe the design and synthesis of a new PEG-based system for the delivery of the cytotoxic camptothecin (CPT) into tumor cells that overexpress luteinizing hormone releasing hormone receptor (LHRHR). A novel functional reducible camptothecin (CPT) block copolymer conjugate was prepared using atom transfer radical polymerization (ATRP). The use of ATRP in the design and synthesis of the copolymer prodrug facilitated high drug loading and specific delivery to tumor cells. The efficacy of the polymer conjugate was evaluated in appropriate cancer cell lines in vitro. Cytotoxic potency was comparable to that of free CPT in LHRHR positive cell lines after 72 hours, whereas little cytotoxicity was observed in LHRHR negative lines. The study also evaluated the effects of polymer-based therapeutics on human peripheral blood mononuclear cells (PBMC). Free CPT demonstrated indiscriminate toxicity against the immune cells, with impairment of PBMC proliferation and a reduction in CD8+, CD4+ T cell populations. The camptothecin (CPT) block copolymer demonstrated a significant improvement in cell proliferation and maintenance of CD8+ cells.

[1]  G. Emons,et al.  Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. , 2002, American journal of obstetrics and gynecology.

[2]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[3]  Hamidreza Ghandehari,et al.  Polymeric conjugates for drug delivery. , 2012, Chemistry of materials : a publication of the American Chemical Society.

[4]  Idriss Blakey,et al.  Multimodal polymer nanoparticles with combined 19F magnetic resonance and optical detection for tunable, targeted, multimodal imaging in vivo. , 2014, Journal of the American Chemical Society.

[5]  R. Duncan,et al.  Nanomedicine(s) under the microscope. , 2011, Molecular pharmaceutics.

[6]  T. Burke,et al.  The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. , 1994, Journal of medicinal chemistry.

[7]  S. Croft,et al.  Preparation and characterisation of amphotericin B-copolymer complex for the treatment of leishmaniasis , 2013 .

[8]  M. Stenzel,et al.  Macromolecular ruthenium complexes as anti-cancer agents , 2012 .

[9]  Jayant Khandare,et al.  Polymer-drug conjugates: Progress in polymeric prodrugs , 2006 .

[10]  P. Couvreur,et al.  Recent trends in the design of anticancer polymer prodrug nanocarriers , 2014 .

[11]  Jason E Gestwicki,et al.  Influencing receptor-ligand binding mechanisms with multivalent ligand architecture. , 2002, Journal of the American Chemical Society.

[12]  I. Warner,et al.  Spectroscopic and photophysical studies of the anticancer drug: Camptothecin , 1997 .

[13]  You Han Bae,et al.  Polymer Architecture and Drug Delivery , 2006, Pharmaceutical Research.

[14]  G. Dranoff,et al.  Experimental mouse tumour models: what can be learnt about human cancer immunology? , 2011, Nature Reviews Immunology.

[15]  N. M. Zaki,et al.  Gateways for the intracellular access of nanocarriers: a review of receptor-mediated endocytosis mechanisms and of strategies in receptor targeting , 2010, Expert opinion on drug delivery.

[16]  V. Torchilin.  Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[17]  B. Chauffert,et al.  CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative , 2004, European journal of immunology.

[18]  Weiping Zou,et al.  Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.

[19]  P. Caliceti,et al.  In situ growth of side-chain PEG polymers from functionalized human growth hormone-a new technique for preparation of enhanced protein-polymer conjugates. , 2010, Bioconjugate chemistry.

[20]  F. Kiessling,et al.  Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[21]  J. Ji,et al.  Biocompatible and biodegradable polymersomes for pH-triggered drug release , 2011 .

[22]  R. Duncan.  Polymer therapeutics as nanomedicines: new perspectives. , 2011, Current opinion in biotechnology.

[23]  G. Hostetter,et al.  Preclinical Investigation of Nanoparticle Albumin-Bound Paclitaxel as a Potential Treatment for Adrenocortical Cancer , 2012, Annals of surgery.

[24]  D. Hafler,et al.  FOXP3+ regulatory T cells in the human immune system , 2010, Nature Reviews Immunology.

[25]  P. Cullis,et al.  Drug Delivery Systems: Entering the Mainstream , 2004, Science.

[26]  S. Dharap,et al.  Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Sarit S. Agasti,et al.  Drug delivery using nanoparticle-stabilized nanocapsules. , 2011, Angewandte Chemie.

[28]  G. Emons,et al.  Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. , 2002, The Journal of clinical endocrinology and metabolism.

[29]  Kinam Park,et al.  Targeted drug delivery to tumors: myths, reality and possibility. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[30]  N. Blackett,et al.  Cell Proliferation and the Action of Cytotoxic Agents on Haemopoietic Tissue , 1972, British journal of haematology.

[31]  S. Dharap,et al.  Targeted Proapoptotic LHRH-BH3 Peptide , 2003, Pharmaceutical Research.

[32]  M. Vicent,et al.  Polymer-drug conjugates for novel molecular targets. , 2010, Nanomedicine.

[33]  Krzysztof Matyjaszewski,et al.  Atom Transfer Radical Polymerization (ATRP): Current Status and Future Perspectives , 2012 .

[34]  K. Ronacher,et al.  Regulation of Expression of Mammalian Gonadotrophin‐Releasing Hormone Receptor Genes , 2005, Journal of neuroendocrinology.

[35]  Ming-zong Li,et al.  QSAR studies of 20(S)-camptothecin analogues as antitumor agents , 2005 .

[36]  V. Torchilin,et al.  Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[37]  H. Maeda,et al.  The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. , 2013, Advanced drug delivery reviews.

[38]  E. Eisenhauer,et al.  Current perspectives on camptothecins in cancer treatment. , 1996, British Journal of Cancer.

[39]  K. Matyjaszewski,et al.  Synthesis of Functional Polystyrenes by Atom Transfer Radical Polymerization Using Protected and Unprotected Carboxylic Acid Initiators , 1999 .